PBAC's latest decision on Methoxyflurane: Recommended with restriction (2008). Considered for For the relief of pain in wound dressings or trauma in patients aged 2-18 years where alternate treatments are unsuitable; and for use in an Emergency Drug (Doctor’s Bag) Supplies.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
—
Submissions
1
first 2008
Submissions
1
2008 → 2008
Eligible population
patients aged 2-18 years with upper limb fracture or venepuncture
Therapy area
Pain
Line of therapy
Not applicable
Evidence base
RCT | Non-randomised studies
Primary endpoint
Pain relief
Key trials
Chin R et al (2002)
Comparator
placebo
Economic model
CUA
Budget impact
$10M
Eligible patients/year
10,000
ICER note
ICER stated as 'less than $15,000 per responder' but this is not a numeric ICER in standard AUD/QALY bands and uses a non-standard outcome metric (responders rather than QALYs/LYs). Document does not provide a conventional ICER range.